Fig. 1

cNDC80 in gliomas: characterization and expression. A The splicing pattern and genomic location of the gene hsa_circ_0046706(526 bp) are shown in a schematic figure. B Sanger sequencing provides a schematic depiction of cNDC80’s structure. C The cNDC80 primers (167 bp) were verified using agarose gel electrophoresis. The arrow represents the “head to tail” splicing sites of cNDC80. D Eight normal brain tissues (NBTs), fifteen low-grade gliomas (LGGs), and thirty high-grade gliomas (HGGs) were analyzed for cNDC80 expression using qRT–PCR. E Construction of the cNDC80 and MOCK plasmid is shown schematically. F qRT–PCR was used to assess cNDC80 expression in U87 cells. G Primers such as oligo (dT)18 or random hexamer were used for the reverse transcription experiments. The relative RNA levels were determined by RT-qPCR using random hexamer primers as a standard. H The relative RNA levels in U87 cells were assessed by qRT–PCR at the given time periods after actinomycin D treatment. I After being treated with RNase R or a mock, the relative RNA levels in total RNAs obtained from U87 cells were assessed by qRT–qPCR. J Cellular RNA fractionation assays analyzed the cellular distribution of cNDC80. As cytoplasmic and nuclear positive controls, ACTB and U2 were utilized, respectively. K Fluorescence in situ hybridization (FISH) was used to investigate the cellular distribution of cNDC80. Green denotes the cNDC80. DAPI was applied to stain the nuclear. Scale bar, 100 μm. Each experiment was conducted three times, and the findings are shown as mean ± SD. (***P < 0.001, ****P < 0.0001)